| |
Cameroon is a West African nation of about 16 million people. It is relatively stable politically, and its economy, largely dependent on petroleum and cocoa exports, is strong in comparison with many other sub-saharan countries.
The HIV-burden in Cameroon is estimated at almost 12 percent of the 15-49 age population. Important HIV-related research is being conducted in Cameroon; almost every known strain of HIV, including the rare O clade HIV-1, can be found in the country (Source: CRISP database).
Malaria is endemic and is the leading cause sickness and mortality in Cameroon. It accounts for as many as half of all medical consultations, 30 percent of hospitalizations, and more than a quarter of work-days lost. Two-thirds of malaria cases in some locations are chloroquine resistant.
The WHO has estimated a tuberculosis death rate of 61 per 100,000 for the country in 2000. Nine of ten provinces are covered by Cameroon's National Tuberculosis Control Program (NTCP).
Sources: CIA World Factbook, UNAIDS, GFATM, United Nations Statistics Division
|
|
|
| |
Cameroon has developed a National Strategic Plan Against AIDS, and there is high level political commitment to fighting HIV/AIDS evidenced by both Cameroon's President and its Minister of Health. Priority action areas for the HIV/AIDS campaign include: - prevention targeting youth and women
- involvement of employers and religious communities
- condom distribution
- prevention of STIs
- blood supply safety, and
- HIV surveillance.
Cameroon's strategic plan for fighting HIV/AIDS is expected to cost $189 million over five years; a financial gap of $110 million exists in meeting implementation costs. Cameroon is one of 13 nations taking part in the UNAIDS Accelerating Access Initiative (AAI), allowing it to purchase HIV/AIDS drugs from pharmaceutical companies at reduced prices.
Cameroon is implementing the DOTS program in its response to TB, and in 2000 WHO estimated that 75 percent of TB cases were treated under DOTS protocols. Due to a lack of funding patients receiving TB treatment have been expected to pay $7.50. A recently approved (Round 3) GFATM grant will allow for the free provision of TB treatment, and greatly increase the resources of the National TB Control Program (NTCP), which had operated without a telephone, fax, email, or vehicle.
Sources: UNAIDS, United Nations Statistics Division, GFATM
|
|
|
| |
| Total population. mid-2009 |
18.9 (millions) |
| HIV prevalence 15-49, 2007/2008
|
5.1% |
| Tuberculosis death rate |
31/100,000 population |
| Prevalence of tuberculosis per 100,000 population, 2000 |
270 |
| Prevalence of tuberculosis per 100,000 population, 2004 |
227 |
| % Tuberculosis detection rate under DOTS, 2001 |
45 |
| % Tuberculosis detection rate under DOTS, 2004 |
92 |
| % Tuberculosis treatment success rate under DOTS, 2000 |
77 |
| Malaria death rate (children under 5) |
620/100,000 population |
| GNI PPP Per Capita, 2008 |
2,180 (US$) |
| Life expectancy at birth |
52 years |
| Infant mortality rate |
74/1,000 live births |
| Total fertility rate |
4.7 per woman |
| Crude birth rate |
36/1,000 population |
| Crude death rate |
13/1,000 population |
| Adult male literacy level |
92% (pct. 15+ literate) |
| Adult female literacy level |
88% (pct. 15+ literate) |
| Contraceptive prevalence rate, modern methods |
12% of women in union |
| Estimated number of people living with HIV: Adults and Children, 2005 |
510,000 |
| Estimated number of people living with HIV: Adults and children, end 2003 |
560,000 |
| Estimated number of people living with HIV: Adults and children, end 2001 |
530,000 |
| Estimated number of people living with HIV: Adults (15+), 2005 |
470,000 |
| Estimated number of people living with HIV: Adults (15-49), end 2003 |
520,000 |
| Estimated number of people living with HIV: Adults (15-49), end 2001 |
500,000 |
| Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 |
5.5% |
| Estimated number of people living with HIV: Women (15+), 2005 |
290,000 |
| Estimated number of people living with HIV: Women 15-49, end 2003 |
290,000 |
| Estimated number of people living with HIV: Women 15-49, end 2001 |
280,000 |
| Estimated number of people living with HIV: Children (0-14), 2005 |
43,000 |
| Estimated number of people living with HIV: Children (0-14), end 2003 |
43,000 |
| Estimated number of people living with HIV: Children (0-14), end 2001 |
39,000 |
| Estimated number of AIDS deaths: Adults and children, 2005 |
46,000 |
| AIDS deaths in adults and children, end 2003
|
49,000 |
| AIDS deaths in adults and children, end 2001
|
41,000 |
| Estimated number of orphans due to AIDS: Children (0-17), 2005 |
240,000 |
| Orphans due to AIDS (0-17), living 2003
|
240,000 |
| Orphans due to AIDS (0-17), living 2001
|
170,000 |
| % Women (15-49), currently married or living with a partner, who have ever discussed AIDS prevention with their husband or partner |
59% |
Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.
|
|
|
| |
Cameroon's public health care system includes: - 1 university teaching hospital
- 3 central hospitals
- 10 private hospitals
- 136 district hospitals
In addition there are public medical centers, mission hospitals, and there are some private clinics and hospitals. Cameroon has 18 approved treatment centers with the capacity to provide HAART treatment for PLWHA. The Ministry of Public Health's annual budget for 1998/1999 was $6.35 million.
The WHO estimates that Cameroon had 7.4 physicians and 36.7 nurses per 100,000 population in 1996.
Sources: Ako et al, Reproductive Health in Cameroon, WHO
|
|
|
| |
|
|
|
|
|
|
| NIH |
Drug Development and Conservation of Biodiversity in West-central Africa |
HIV/AIDS,Malaria |
Drug Development |
|
| |
(Principal Investigator: Brian Schuster. 1998-2003.) This project, directed by Colonel Brian Schuster of Walter Reed Army Hospital, has developed a...
|
| NIH |
Clinical and Mucosal Interactions Between HSV and HIV |
HIV/AIDS |
Drug Development |
Prevention |
| |
(PI: Lawrence Corey. 2003-2008.) This research project includes a double blind cross over study of the efficacy of daily acyclovir treatment in...
|
| NIH |
Evolution and Properties of HIV/SIV Strains in Cameroon |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Phillipe Nyambi. 2000-2004.) This study investigates possible cross-species transmission of the M, N and O varieties of HIV-1. It also examines...
|
| NIH |
Immunologic Characteristics of HIV Isolates in Cameroon |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Phillipe Nyambi. 2000-2003.) This study compares immunological characteristics of HIV-1 clades A-J in Cameroon.
|
| NIH |
The Emergence of HIV Genetic Diversity in Cameroon |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Nathan Wolfe. 1999-2003.) This study investigates the relationship between lentiviruses found among primate hunters in Cameroon, and the...
|
| NIH |
Virus-cell interaction/host factors in HIV pathogenesis |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Indira Hewlett. 2002) A component of this study is investigating new strategies for the identifications of new variants and recombinants of HIV...
|
| NIH |
Detection, quantitation and characterization of HIV |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Indira Hewlett. 2002) This study is examining the molecular evolution of various strains of HIV found in Cameroon.
|
| NIH |
Immunologic Relatedness Among and Between HIV1 Clades |
HIV/AIDS |
Epidemiology |
Drug Development |
| |
(PI: Susan Zolla-Pazner. 1994-2004.) The objective of this study includes analyzing human monoclonal antibodies (mAbs) from blood specimens...
|
| NIH |
Natural SIV reservoirs and human zoonitic risk |
HIV/AIDS |
Epidemiology |
|
| |
(PI: Beatrice Hahn. 2001-2006.) This study aims to determine the full spectrum and prevalence of SIV in both human and non-human populations in...
|
| NIH |
Genetic Variation in HIV Disease |
HIV/AIDS |
Epidemiology |
Drug Development |
| |
(PI: Indira Hewlitt. 2003?) This grant covers several different research activities relating to genetically diverse strains of HIV found in...
|
| NIH |
Population genomics of Mosquito An. gambiae in Africa |
Malaria |
Epidemiology |
Prevention |
| |
(PI: Gregory Lanzaro. 1996-2007.) This study examines population size, patterns of gene flow and breeding stucture for the populations of mosquito...
|
| NIH |
Th2 Bias Effect On Malarial Immunity in Cameroon |
Malaria |
Epidemiology |
|
| |
(PI: Diane Taylor. 1998-2005.) This study examines the effect of body-chemistry changes during pregnancy on naturally occurring malarial immunity...
|
| NIH |
Malarial Immunity in Pregnant Cameronian Women |
Malaria |
Prevention |
|
| |
National Institute of Allergy and Infectious Diseases, University of Hawaii, University of Yaounde. The Ministry of Health in Cameroon has...
|
| NIH |
Fogarty AIDS International Training & Research Program |
HIV/AIDS |
Capacity |
|
| |
(PI: Chris Beyrer. 1998-2008.) This Fogarty grant allows Johnns Hopkins University to provide training to 1 long-term trainee, 34 short-term...
|
| NIH |
Training Program in TB and HIV Prevention and Treatment |
HIV/AIDS,Tuberculosis |
Capacity |
Prevention |
| |
(PI: Susan Zolla-Pazner. 2000-2005.) This program of the NYU Center for AIDS Research supports clinical and research training for scientists and...
|
| International |
DFID (The United Kingdom) |
HIV/AIDS,Tuberculosis |
Drug Development |
Prevention,Capacity |
| |
In 2002 DFID announced a five-year $23 million study in Cameroon and several other African nations to develop a microbicide effective against HIV...
|
| International |
Molecular Diversity of HIV-1 Group 0 Strains and Treatment Management in Cameroon |
HIV/AIDS |
Drug Development |
General |
| |
French National Agency for Research on AIDS and Viral Hepatitis, Hôpital Central, Hôpital Militaire, Hôpital Général, Hôpital de la CNPS (PI:...
|
| International |
Evaluation of Three Strategies of Second-Line Antiretroviral Treatment in Africa (Dakar-Bobo-Dioulasso-Yaoundé) (2LADY) |
HIV/AIDS |
Drug Development |
|
| |
French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Janssen Pharmaceutica N.V. Belgium (PIs: Sinata Koulla Shiro,...
|
| International |
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) |
HIV/AIDS |
Drug Development |
|
| |
French National Agency for Research on AIDS and Viral Hepatitis (PIs: Landman Roland, Sow Papa Salif, Koulla Shiro Sinata). This trial will enroll...
|
| International |
Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women |
HIV/AIDS |
Drug Development |
Prevention |
| |
Laval University, Canadian Institutes of Health Research, Centre Hospitalier de l'Universite Laval. (PI: Michel Bergeron). This trial will allow...
|
| International |
ATAQ Easy: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria |
Malaria |
Drug Development |
|
| |
Sanofi-Aventis (Study Director: Valérie Lameyre). This study will compare and contrast the efficacy of three treatment regimens for malaria in...
|
| International |
Multisectoral HIV/AIDS Project (World Bank) |
HIV/AIDS |
Capacity |
|
| |
The World Bank is providing $50 million for a Multisectoral HIV/AIDS Project to be implemented over the 2001-2005 period. The project information...
|
| International |
Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) |
HIV/AIDS,Tuberculosis,Malaria |
General |
|
| |
GFATM has appropriated $34.6 million over two years for fighting these contagious diseases in Cameroon. The appropriations included:...
|
| NGO |
A Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Acyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons in Cameroon. |
HIV/AIDS |
Drug Development |
Prevention |
| |
Fred Hutchinson Cancer Research Center Institute for the Development of Africa. (PI: Francois Xavier Mbopi-Keou; study start March 2005). In this...
|
| NGO |
MIM/TDR Grants for Malaria Research |
Malaria |
Epidemiology |
|
| |
A Multilateral Initiative on Malaria (MIM)/TDR Task Force awarded one grant in the amount of $77,000 for malaria research in Cameroon in 2002. The...
|
| Foundation |
Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon |
Malaria |
Drug Development |
|
| |
Gates Malaria Partnership (PI: Wilfred F. Mbacham). This study will compare the effectiveness and safety of Artemisinin-based combination therapy...
|
|
|
|